Novartis and Yuhan Corporation will co-promote a new COPD complex

‘Xoterna Breezhaler,’ the fixed capacity complex consisting of two bronchodilators, the long acting β2-agonist (LABA) indacaterol and the long-acting muscarinic antagonist (LAMA) glycopyrronium, is going to be launched as the phase-1 maintenance therapy drug to relieve the chronic obstructive pulmonary disease (COPD) symptom.

Xoterna Breezhaler, developed as a LABA/LAMA complex which is a sing...